

SABCS 2015 – NSABP (NRG) Presentation Schedule
General Session, Poster Discussion, and Poster Presentations

Disease Site	Breast	
Wednesday, December 9, 2015		
	Time/Location	Study #
<p>The Contribution of NSABP Clinical Trials to the Management of Early Breast Cancer <i>Norman Wolmark</i></p>	<p>11:15 am - 12:00 pm Hall D William L. McGuire Memorial Lecture Program # ML1 Oral</p>	
<p>Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor (HR) positive and HER2-negative breast cancer (BC): SWOG/NRG/Alliance S1207 (NCT01674140) <i>Contributors: Chavez-MacGregor M, Barlow WE, Puzstai L, Goetz MP, Rastogi P, Ganz PA, Mamounas EP, Paik S, Bandos H, Gralow J, Lew DL, Hortobagyi GN.</i></p>	<p>5:00 pm – 7:00 pm Halls A-B Ongoing Clinical Trials: Targeted Therapies Program # OT1-03-11 Poster</p>	<p>SWOG/NRG/ Alliance S1207</p>
Thursday, December 10, 2015		
	Time/Location	Study #
<p>NSABP FB-7: A phase II randomized trial evaluating neoadjuvant therapy with weekly paclitaxel (P) plus neratinib (N) or trastuzumab (T) or neratinib and trastuzumab (N+T) followed by doxorubicin and cyclophosphamide (AC) with postoperative T in women with locally advanced HER2-positive breast cancer. <i>Contributors: Jacobs SA, Robidoux A, Garcia JMP, Abraham J, La Verde N, Orcutt JM, Cazzaniga ME, Calvo L, Aguirre E, Buyse M, Pogue-Geile KL, Srinivasan A, Song N, Balousek AD, Wolmark N.</i></p>	<p>5:00 pm – 7:00 pm Ballroom A Poster Discussion 5: HER2 Program # PD5-04 Poster Discussion: 5-6 pm</p>	<p>NSABP FB-7</p>
<p>NRG Oncology/NSABP B-51/RTOG 1304: A phase III clinical trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) will reduce invasive cancer events in patients (pts) with positive axillary (Ax) nodes who are ypN0 after neoadjuvant chemotherapy (NC). <i>Contributors: Mamounas, EP, Bandos H, White JR, Julian TB, Khan AJ, Shaitelman SF, Torres MA, Vicini FA, Ganz PA, McCloskey SA, Paik S, Gupta N, Li XA, DiCostanzo DJ, Costantino JP, Curran Jr WJ, Wolmark N.</i></p>	<p>5:00 pm – 7:00 pm Halls A-B Ongoing Clinical Trials: Surgery and Radiation Program # OT2-02-02 Poster</p>	<p>NSABP B-51/ RTOG1304</p>
Friday, December 11, 2015		
	Time/Location	Study #
<p>Patient-reported outcome (PRO) results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) vs tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy. <i>Contributors: Ganz PA, Cecchini RS, Julian TB, Margolese RG, Costantino JP, Vallow LA, Albain KS, Whitworth PW, Cianfrocca ME, Brufsky A, Gross HM, Soori GS, Hopkins JO, Fehrenbacher L, Sturtz K, Wozniak TF, Seay TE, Mamounas EP, Wolmark N.</i></p>	<p>4:00 - 4:15 pm Hall D General Session 6: 3:15 pm – 5:00 pm Program # S6-04 Oral</p>	<p>NSABP B-35</p>
Saturday, December 12, 2015		
	Time/Location	Study #
<p>Results from NRG oncology/NSABP protocol DMP-1: Women's decision-making in breast cancer risk reduction. <i>Contributors: Holmberg C, Bandos H, Fagerlin A, Bevers TB, Battaglia TA, Wickerham DL, McCaskill-Stevens W.</i></p>	<p>7:30 am - 9:00 am Hall D Poster Session 6: Epidemiology, Risk, and Prevention - Other Program # P6-10-01</p>	<p>NSABP DMP-1</p>